Professor Barbara Fazekas de St Groth, Head of T Cell Biology Group at Centenary. Source: The Australian
Professor Barbara Fazekas de St Groth, Head of the T Cell Biology Group at Centenary, has featured prominently in this week’s Weekend Australian. Her work in targeted immunosupression and the “odd behaviour” of immune cells in the skin has captured the interest of the media, and is a great acknowledgement of the ground-breaking work that Barbara does.
The Weekend Australian story reported on Barbara’s research in immune defence and her discovery that in the upper most layer of the skin, cells were suppressing the immune response, preventing a reaction and inducing tolerance.
Dr Nikolas Haass, Head of the Melanoma Research lab, passes the Charity Cheer Zone at the 2011 City2Surf
If the City2Surf is on your ‘to do’ list this year, why not join Centenary’s Run4Research team? Centenary is one of a select group of charities that has 30 spots in the Gold Charity Zone and registrations are now open.
A Gold Charity place means that you will start just behind the Red Zone (the elite group) so if you are a serious runner (or not!), you will have a big advantage.
The entry fee is $125 and you’ll need to raise $1000 for medical research at Centenary Institute, so that gives you almost 6 months to fundraise. If you raise more than $1500 this year, then your entry fee for next year will be waived.
Leisl Holterman, Centenary's Fundraising Coordinator, with her brother Greg after swimming 2km in the Cole Classic.
Last Sunday, Centenary’s Fundraising Coordinator, Leisl Holterman, braved a strong swell at Manly Beach to swim two kilometres in the ocean while raising funds for melanoma research at the very institute she works for.
Leisl finished the race in 47 minutes and came 54th out of 95 in her age group, an amazing feat given that she has never swum in the ocean before.
But what she is most proud of, is raising $1,300 for melanoma research at Centenary because the cause is close to her heart.
Professor Geoff McCaughan, Head of Centenary's Liver Immunobiology Group
The Therapeutic Goods Administration has approved the hepatitis C medication, Victrelis. There are about 217,000 Australians living with chronic hepatitis C. Victrelis has been found to be suitable for the treatment of 40 per cent of patients. Unlike hepatitis A and B, there is no vaccine, making better treatments more important.
The Head of the Centenary Institute’s liver unit, Professor Geoff McCaughan, says the approval is a major breakthrough for patients.